

GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends

Company Report | 2025-02-27 | 147 pages | Quaintel Research

AVAILABLE LICENSES:

- Single User Price \$175.00
- Multi User Price \$195.00
- Enterprise User Price \$225.00

Report description:

Report Summary

GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of GSK plc's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about GSK plc, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses GSK plc's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of GSK plc's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers GSK plc's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares GSK plc's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by GSK plc, enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline and French firm. GSK aims to deliver impactful medicines, vaccines, and treatments, positively affecting the lives of 2.5 billion people by 2030. It invests heavily in research and development, utilizing advancements like AI and robotics for faster production. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others.

GSK plc in the News:-

- 15-Feb-2025 - Penmenvry, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
- 31-Jan-2025 - European Commission authorises ViiV Healthcare's long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
- 28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
- 28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
- 27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research

Scope

- **Tactical Analysis:-** Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- **Business Strategy:-** Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- **Financial Position:-** Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- **Company Fundamentals:-** These fundamentals offer valuable insights into the company's history, operations, leadership, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

geographical presence, aiding in a comprehensive understanding of the organization.

□ **Competitive Landscape:-** An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

□ Comprehensive Understanding of the GSK plc's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.

□ Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.

□ Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.

□ Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.

□ Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.

□ Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company GSK plc:

□ GSK plc Porter's Five Forces Analysis

□ GSK plc VRIO Analysis

□ GSK plc BCG Analysis

□ GSK plc Segmentation, Targeting and Positioning (STP) Analysis

□ GSK plc Ansoff Matrix Analysis

Table of Contents:

Table of Contents

COMPANY EXECUTIVE SUMMARY 1

Table of Contents 2

Tables 7

Charts 8

GSK plc - Key Company Facts 9

GSK plc - Company Description 10

GSK plc - Top Executives 11

GSK plc- Head Office & Locations 13

Head Office - Country 13

GSK plc - Products and Services 14

Products 14

Services 15

GSK plc - Corporate Strategy 18

GSK plc - Business Description 25

Vaccines 26

Specialty Medicines 26

General Medicines 27

GSK plc - ESG Spotlight 28

Environment 28

Social 29

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Corporate Governance	30
GSK plc - SWOT Analysis	31
Overview	31
Strengths	33
Weaknesses	36
Opportunities	38
Threats	41
GSK plc - PESTLE Analysis	42
Overview	42
Political Factors	44
Economic Factors	45
Social Factors	47
Technological Factors	49
Legal Factors	51
Environmental Factors	52
GSK plc - Chapter1 name	54
Heading1	54
Heading2	54
GSK plc - Chapter1 name	55
Heading1	55
Heading2	55
GSK plc- Chapter1 name	56
Heading1	56
Heading2	56
GSK plc - Financial Deep Dive	57
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price)	57
Profit and Loss Statement	59
Summary of Profit and Loss Statement	59
Balance Sheet	61
Summary of Balance Sheet	61
Cash Flow Statement	63
Summary of Cash Flow Statement	63
Key Financial Ratio Analysis	65
GSK plc - Ratio Charts	66
Activity Ratio Charts	66
Growth Ratios Charts	67
Leverage Ratio Charts	68
Liquidity Ratio Charts	69
Profitability Ratio Charts	70
Competing Players	71
Snapshot of Competing Players	72
Roche Holding AG	72
Key Company Facts	72
Company Description	72
Johnson & Johnson	73
Key Company Facts	73
Company Description	73

Novartis AG	74
Key Company Facts	74
Company Description	74
Pfizer Inc.	75
Key Company Facts	75
Company Description	75
Merck & Co., Inc.	76
Key Company Facts	76
Company Description	76
GSK plc - In the News	77
15-Feb-2025 - Penmeny, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY	77
31-Jan-2025 - European Commission authorises ViiV Healthcare's long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents	79
28-Jan-2025 - Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP	80
28-Jan-2025 - Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP	82
27-Jan-2025 - GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research	84
27-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency	85
10-Jan-2025 - GSK's Shingrix new prefilled syringe presentation accepted for review by US FDA	86
23-May-2024 - Statement: Zantac (ranitidine) litigation - Valadez and Williams cases	86
21-May-2024 - GSK announces positive results from phase III severe asthma trials of depemokimab	86
24-Apr-2024 - US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer	89
17-Apr-2024 - EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	92
17-Apr-2024 - New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	94
16-Apr-2024 - GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA	96
16-Mar-2024 - Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer	98
07-Mar-2024 - GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma	100
06-Mar-2024 - ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges	102
29-Feb-2024 - GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director	105
28-Feb-2024 - ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV	107
GSK plc - Key Deals	109
24-Feb-2025 - GSK completes acquisition of IDRx, Inc.	109
13-Jan-2025 - GSK enters agreement to acquire IDRx, Inc.	110
05-Dec-2024 - GSK and Zhifei revise and extend strategic vaccine collaboration in China	112
29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline	112
29-Oct-2024 - GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline	114
21-Oct-2024 - GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease	114
16-May-2024 - GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)	117

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15-Feb-2024 - GSK completes acquisition of Aiolos Bio	119
09-Jan-2024 - GSK enters agreement to acquire Aiolos Bio	119
20-Dec-2023 - GSK enters exclusive license agreement with Hansoh for HS-20093	122
31-Oct-2023 - GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen	124
09-Oct-2023 - GSK and Zhifei announce exclusive strategic vaccine partnership in China	127
28-Jun-2023 - GSK completes acquisition of BELLUS Health	130
18-Apr-2023 - GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health	132
30-Mar-2023 - GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection	135
13-Dec-2022 - GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets	138
Appendix	141
Definitions	141
SWOT Analysis	141
PESTLE Analysis	141
Value Chain Analysis	141
ESG Spotlight	141
Financial Deep Dive	141
Financial Ratios -	142
Activity Ratios	142
Growth Ratios	143
Leverage Ratios	144
Liquidity Ratios	145
Market Ratios	146
Profitability Ratios	146
Research Methodology	147
Disclaimer	148
Contact Us	148

GSK plc (GSK:LSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends

Company Report | 2025-02-27 | 147 pages | Quaintel Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$175.00
	Multi User Price	\$195.00
	Enterprise User Price	\$225.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-08

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

A large, empty rectangular box with a thin black border, intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com